Previous 10 | Next 10 |
2024-01-23 08:25:53 ET More on Pre-market losers & stocks. Mesoblast Has Major Hurdles Holding The Fort: Mesoblast's Path Towards Overcoming FDA Rejection Mesoblast rises after cell therapy gets FDA rare pediatric disease designation MSP Recovery stock tu...
2024-01-22 12:31:12 ET Gainers: Sagimet Biosciences ( SGMT ) +106% . Rail Vision Ltd ( RVSN ) +51% . Digital World Acquisition Corp ( DWAC ) +49% . Bullfrog AI Holdings ( BFRG ) +38% . CXApp ( CXAI ) +34% . Phunware ( PHUN ...
2024-01-22 10:00:11 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-19 10:44:08 ET More on Processa Pharmaceuticals Processa Pharmaceuticals to effect 1-for-20 reverse stock split to regain compliance with Nasdaq rule Processa falls after update on chemotherapy development Seeking Alpha’s Quant Rating on Processa Pharm...
2024-01-19 08:49:59 ET DENVER, Colo., Jan. 19, 2024 (www.247marketnews.com)- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stated, this morning, that... For further details see: Processa Pharmaceuticals (NASDAQ: PCSA) Expanding its NGC-Cap Program into Advanced or Metastatic Breast Cancer
FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design HANOVER, MD, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmac...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, has announced a 1-for-20 reverse stock split. The reverse split was initiall...
2024-01-18 08:04:56 ET More on Processa Pharmaceuticals Processa falls after update on chemotherapy development Seeking Alpha’s Quant Rating on Processa Pharmaceuticals Historical earnings data for Processa Pharmaceuticals Financial information for Pro...
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety ...
HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety ...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...